pathogen
initi
infect
human
mucos
surfac
therefor
mucos
vaccin
especi
oral
intranas
administr
rout
highli
desir
infecti
diseas
meanwhil
proteinbas
antigen
provid
safer
altern
whole
pathogen
dna
base
one
vaccin
develop
howev
uniqu
biopharmaceut
hurdl
intranas
oral
deliv
protein
vaccin
need
overcom
reach
site
target
rel
low
immunogen
well
low
stabil
protein
antigen
requir
thought
finetun
mucos
vaccin
formul
includ
select
immunostimul
identif
suitabl
vaccin
deliveri
system
determin
exact
composit
manufactur
condit
review
aim
provid
uptod
survey
protein
antigenbas
vaccin
formul
develop
includ
usag
immunostimul
optim
vaccin
deliveri
system
intranas
oral
administr
keyword
mucos
vaccin
protein
antigen
adjuv
immunostimul
vaccin
deliveri
system
electron
supplementari
materi
onlin
version
articl
subunit
protein
antigen
much
safer
altern
whole
pathogen
viral
vectorbas
antigen
sinc
lower
risk
caus
diseas
immunogen
proteinbas
mucos
vaccin
review
effect
way
reduc
diseas
vaccin
undergon
long
way
human
histori
ever
sinc
edward
jenner
use
cowpox
viru
vaccin
prevent
smallpox
vaccin
wide
use
diseas
includ
small
pox
diphtheria
tetanu
yellow
fever
pertussi
haemophilu
influenza
type
b
diseas
poliomyel
measl
mump
rubella
typhoid
rabi
anthrax
rotaviru
shingl
meningococc
pneumococc
diseas
japanes
enceph
varicella
rotaviru
lyme
diseas
tuberculosi
hepat
influenza
jariyapong
et
al
vaccin
develop
evolv
natur
exposur
empir
inactivatedattenu
pathogen
final
subunit
antigen
structurefunct
properli
design
nowaday
dormitz
et
al
de
gregorio
rappuoli
pathogen
initi
infect
mucos
surfac
respiratori
gastrointestin
urogenit
system
marasini
et
al
first
defens
line
human
bodi
mucos
immun
highli
desir
provid
effici
longlast
protect
pathogen
invas
yet
commerci
vaccin
deliv
system
induc
humor
immun
protect
without
pathogenspecif
mucos
immun
therefor
mucos
vaccin
highli
advantag
infecti
diseas
inhal
ingest
sexual
transmit
influenza
tamura
kurata
coronavirus
hiv
rappuoli
aderem
etc
reader
refer
sever
review
describ
mucos
vaccin
develop
divers
infecti
diseas
even
cancer
holmgren
czerkinski
neutra
kozlowski
lyck
gener
sever
factor
consid
effici
safe
mucos
vaccin
develop
includ
antigen
adjuv
formul
administr
rout
anim
model
efficaci
safeti
evalu
effect
vaccin
often
contain
follow
compon
antigen
elicit
specif
adapt
immun
respons
immunostimul
stimul
innat
immun
system
deliveri
system
rightplac
righttim
vaccin
deliveri
pashin
et
al
although
virusand
dnabas
antigen
may
effect
safeti
concern
remain
due
exist
genecod
materi
may
revert
virul
diseasecaus
state
protein
antigen
present
quit
promis
altern
vaccin
develop
due
follow
characterist
absenc
infecti
materi
like
code
gene
capabl
induc
antigenspecif
antibodi
possibl
chemic
modif
readi
larg
scale
manufactur
loom
pandem
howev
proteinbas
antigen
limit
physiolog
instabl
low
immunogen
demand
potent
immunostimul
effici
deliveri
system
accomplish
effect
vaccin
product
review
uptod
achiev
mucosa
prophylact
vaccin
develop
proteinbas
antigen
defend
variou
infecti
diseas
includ
tetanu
influenza
hepat
sar
mer
hiv
etc
field
vast
review
mere
concentr
recent
relev
studi
protein
antigen
adjuv
deliveri
system
oral
intranas
vaccin
vaccin
deliv
variou
administr
rout
includ
parenter
rout
like
intramuscular
subcutan
inject
mucos
rout
intranas
oral
vagin
rectal
tract
mucos
vaccin
sever
forese
advantag
needl
free
better
patient
complianc
strong
mucos
immun
besid
system
immun
respons
provid
first
barrier
infect
initi
mucos
surfac
potenti
overcom
barrier
preexist
immun
caus
previou
parenter
vaccin
belyakov
et
al
intranas
oral
vaccin
attract
administr
rout
among
variou
mucos
administr
larg
due
better
patient
complianc
nasal
deliveri
prefer
due
highli
vascular
mucos
surfac
area
cm
nasopharyng
compart
vaccin
uptak
abil
induc
immun
protect
local
nasal
interconnect
oral
distant
mucos
site
vagin
colorect
region
rel
low
dose
achiev
requir
immun
compar
rout
almeida
alpar
olszewska
steward
holmgren
czerkinski
oral
deliveri
advantag
consid
superior
patient
complianc
easi
administr
mass
immun
capac
marasini
et
al
especi
come
plantderiv
protein
antigen
veterinari
vaccin
exampl
plantderiv
recombin
protein
vaccin
effici
cost
effect
oral
administr
without
protein
purif
complic
formul
step
algaebas
oral
recombin
vaccin
specht
mayfield
meanwhil
plantderiv
protein
antigen
suggest
use
boost
vaccin
oral
feed
anim
antigenexpress
food
prime
realiz
convent
vaccin
lamphear
et
al
pogrebnyak
et
al
mucos
surfac
protect
larg
special
innat
adapt
mucos
immun
system
innat
immun
system
play
import
role
fight
initi
infect
facilit
gener
adapt
immun
respons
adapt
immun
system
vital
provid
protect
previous
encount
pathogen
mucos
immun
occur
induct
site
call
mucosaassoci
lymphoid
tissu
malt
contain
b
cell
cell
antigen
present
cell
apc
specif
immun
respons
initi
holmgren
czerkinski
lawson
et
al
malt
cover
follicleassoci
epithelium
compris
epithelium
cell
lymphoid
cell
minor
portion
microfoldmembran
cell
fig
cell
gener
recogn
antigen
uptak
cell
lumen
intestinalnas
mucosa
transport
antigen
underli
apc
malt
upon
infect
vaccin
precursor
cell
b
cell
cell
dendrit
cell
induct
site
activ
migrat
popul
local
remot
mucosa
site
common
mucos
immun
system
realiz
system
immun
protect
mucos
respons
occur
local
initi
adjac
interconnect
mucosa
except
intranas
vaccin
could
induc
iga
secret
local
nasal
adjac
oral
mucosa
surfac
also
remot
vagin
rectal
region
holmgren
czerkinski
similar
system
immun
mucos
vaccin
accomplish
three
step
fig
effici
antigen
sampl
uptak
antigen
process
present
apc
b
cell
activ
product
effector
cell
gener
memori
counterpart
product
neutral
antibodi
vital
humor
immun
respons
clear
extracellular
infect
distinguish
system
vaccin
mucos
vaccin
normal
induc
strong
secretori
iga
respons
defend
viral
infect
mucos
surfac
besid
produc
system
serum
igg
neutral
newli
gener
virus
renegar
et
al
cellular
immun
respons
involv
activ
cell
cell
activ
differenti
differ
function
effector
cell
khader
et
al
product
induc
effector
cell
produc
mediat
cellular
respons
intracellular
pathogen
effector
cell
produc
regul
humor
immun
respons
effector
cell
gener
presenc
character
product
critic
involv
defens
pathogen
mucosa
surfac
khader
et
al
khader
et
al
activ
cell
cytotox
lymphocyt
ctl
cytolyt
effect
also
mediat
product
cytokin
like
tumor
necrosi
seder
hill
ctl
respons
critic
protect
intracellular
infect
optim
mucos
vaccin
formul
includ
appropri
combin
antigen
immunostimul
deliveri
carrier
abl
induc
comprehens
seri
protect
immun
respons
demonstr
product
variou
antibodi
igg
iga
etc
ctl
relev
cytokin
fig
pathogen
microb
often
specif
molecular
characterist
known
pathogenassoci
molecular
pattern
pamp
recogn
pathogen
recognit
receptor
prr
mucos
epitheli
cell
apc
prr
gener
membranebound
receptor
tolllik
receptor
tlr
nucleotidebind
oligomer
domain
nod
like
receptor
nlr
ctype
lectin
receptor
clr
kanzler
et
al
devriendt
et
al
park
sensori
pamp
pathogen
prr
dc
pass
andor
b
cell
alter
releas
cytokin
express
costimulatori
molecul
upregul
integrin
adhes
improv
potenc
vaccin
immunostimul
target
prr
often
use
adjuv
activ
prepar
immun
system
react
specif
antigen
immunostimul
could
pamp
deriv
endogen
cytokin
empir
molecul
materi
detail
discuss
section
adjuv
mucos
vaccin
protein
antigen
antigen
process
present
apc
first
requir
mucos
vaccin
guarante
effici
antigen
transport
mucos
epithelium
mucin
malt
realiz
endocytosi
receptormedi
antigen
apic
membran
exocytosi
basolater
membran
cell
enterocyt
neutra
et
al
lawson
et
al
reinek
et
al
one
way
improv
transcytosi
vaccin
cell
epitheli
cell
incorpor
mepitheli
cellspecif
ligand
pathogenexploit
molecul
vaccin
formul
vaccin
reach
malt
underli
mucosa
epithelium
effici
uptak
process
present
antigen
demand
apc
includ
macrophag
dendrit
cell
dc
b
cell
dc
key
apc
bridg
innat
adapt
immun
system
found
prefer
intak
vaccin
formul
pathogenlik
nanoparticl
elamanchili
et
al
klippstein
pozo
hamdi
et
al
thu
quit
number
nanoparticular
vaccin
deliveri
system
base
differ
biomateri
explor
target
prr
dc
mimick
pathogen
properti
enhanc
immun
respons
demento
et
al
park
matur
dc
potent
activ
cell
act
primari
initi
immun
respons
specif
antigen
banchereau
steinman
aforement
properti
function
epitheli
cell
cell
dc
wide
exploit
variou
mucos
target
strategi
discuss
section
vaccin
formul
materi
deliveri
system
antigen
central
element
vaccin
use
induc
antigenspecif
immun
memori
current
variou
type
antigen
includ
whole
inactiv
pathogen
mixtur
liveattenu
organ
vectorbas
recombin
vaccin
subunit
vaccin
includ
dna
rna
isolatedrecombin
protein
glycoprotein
carbohydr
commerci
avail
vaccin
fall
first
second
categori
contain
genet
materi
pathogen
except
includ
proteinbas
subunit
viruslik
particl
vlp
detoxifi
toxoidstoxin
polysaccharideprotein
conjug
http
wwwfdagov
biologicsbloodvaccinesvaccin
approv
vaccin
gener
administ
system
except
mucos
vaccin
compris
whole
inactiv
liveattenu
pathogen
intranas
influenza
vaccin
flumist
medimmun
llc
oral
vaccin
polio
oral
polio
vaccin
cholera
oral
cholera
vaccin
typhoid
fever
vivotif
adenoviru
trade
name
barr
lab
inc
well
rotaviru
infect
rotarix
glaxosmithklin
biolog
live
viral
vector
wide
use
deliveri
system
mucos
vaccin
includ
adenoviru
attenu
influenza
viru
venezuelan
equin
viru
bacillu
poxviru
vector
prevec
et
al
caley
et
al
hiroi
et
al
gherardi
esteban
huang
et
al
wang
et
al
besid
viral
vector
nucleic
acidbas
vaccin
plasmid
dna
rna
also
develop
howev
inactivatedattenu
pathogen
vectorand
dnabas
vaccin
alway
limit
use
due
difficulti
microorgan
cultur
safeti
concern
possibl
revert
virul
state
immunocompromis
host
well
potenti
advers
effect
includ
allerg
autoimmun
reaction
contrast
vaccin
protein
antigen
intrins
safer
whole
pathogenbas
dnabas
antigen
due
absenc
genet
materi
furthermor
technic
matur
mass
product
specif
peptid
recombin
protein
substanti
lower
hurdl
develop
proteinpeptidebas
therapeut
vaccin
degim
celebi
therefor
pathogen
protein
epitop
peptid
provid
promis
altern
antigen
develop
exampl
nabel
group
report
ferritin
nanoparticl
base
ha
deliveri
system
demonstr
potent
broader
immun
protect
influenza
inactiv
viru
vaccin
deliveri
system
ha
mimic
natur
trimer
conform
viru
kanekiyo
et
al
current
approv
oral
intranas
protein
vaccin
yet
extens
effort
report
mucos
vaccin
proteinbas
antigen
variou
infecti
diseas
influenza
yoshikawa
et
al
tamura
kurata
petersson
et
al
rose
et
al
plaqu
eyl
et
al
tripathi
et
al
tetanu
jaganathan
et
al
diphtheria
alpar
et
al
singh
et
al
hepat
b
borg
et
al
borg
et
al
hiv
morri
et
al
sarscov
pogrebnyak
et
al
merscov
zhang
et
al
etc
besid
protein
pathogen
model
protein
antigen
ovalbumin
ova
bovinehuman
serum
albumin
bsahsa
often
use
vaccin
formul
develop
influenza
virus
infect
host
cell
two
surfac
glycoprotein
hemagglutinin
ha
head
region
highli
conserv
stalk
region
neuraminidas
na
annual
influenza
pandem
occur
antigen
properti
ha
na
chang
thu
protein
serv
potenti
candid
influenza
vaccin
antigen
intranas
immun
yoshikawa
et
al
hand
matrix
protein
whose
amino
acid
sequenc
highli
conserv
among
human
influenza
virus
exploit
design
broadspectrum
influenza
vaccin
mould
et
al
sui
et
al
envelop
surfac
glycoprotein
transmembran
glycoprotein
hiv
mediat
hiv
infect
interact
receptor
host
cell
thu
two
protein
short
sequenc
fragment
often
use
antigen
hiv
vaccin
develop
lema
et
al
tetanu
toxoid
tt
kda
protein
produc
bacterium
clostridium
tetani
caus
tetanu
diphtheria
toxoid
dt
acid
protein
secret
pathogen
bacterium
corynebacterium
diphtheria
caus
diphtheria
toxin
main
diseasecaus
contributor
exploit
antigen
vaccin
develop
tetanu
diphtheria
alpar
et
al
fraction
capsular
protein
kda
virul
v
protein
kda
virul
subunit
produc
yesinia
pesti
caus
plaqu
diseas
vaccin
base
v
protein
display
protect
immun
bubon
pneumon
anim
model
williamson
oyston
surfac
antigen
hepat
b
viru
hbsag
viral
envelop
protein
success
use
human
vaccin
induc
effect
immun
protect
hepat
b
krugman
mcaleer
et
al
hbsag
assembl
vlp
recombin
express
host
like
yeast
two
novel
coronavirus
emerg
centuri
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
caus
acut
respiratori
distress
syndrom
lead
high
mortal
receptor
bind
domain
spike
protein
sarscovmerscov
promis
antigen
candid
sinc
bind
human
hostcel
receptor
angiotensinconvert
enzym
peptidas
li
et
al
wong
et
al
graham
et
al
lu
et
al
zhang
et
al
oral
feed
mice
tomato
juic
express
ntermin
fragment
sarscov
spike
protein
induc
sarscovspecif
iga
product
pogrebnyak
et
al
differ
protein
antigen
fuse
gener
combin
vaccin
antigen
two
diseas
time
instanc
enhanc
cross
protect
immun
influenza
respiratori
syncyti
viru
rsv
realiz
intramuscular
vaccin
fusion
subunit
protein
influenza
viru
hemagglutinin
ha
rsv
fusion
f
protein
turner
et
al
protein
antigen
wide
exploit
vaccin
develop
protect
infecti
diseas
serious
limit
gener
low
stabil
immunogen
induc
concert
humor
cellular
immun
respons
thu
optim
formul
includ
select
immunostimul
ideal
deliveri
rout
critic
import
proteinbas
vaccin
often
compromis
time
necessit
use
adjuv
protein
vaccin
improv
humor
cellular
mucos
immun
respons
marciani
adjuv
review
specif
refer
immunostimul
immunepotenti
substanc
stimul
immun
system
activ
increas
activ
compon
immunostimul
compound
macromolecul
complex
boost
maintain
potenti
immun
respons
antigen
gener
use
target
innat
immun
respons
facilit
evolut
adapt
immun
respons
pashin
et
al
reed
et
al
mediat
balanc
humor
cellular
immun
brunner
et
al
immunostimul
contribut
immunostimul
vaccin
affect
antigen
formul
administr
rout
exampl
tlr
agonist
includ
poli
c
cpg
b
mpllp
nlr
ligand
muramyl
dipeptid
mdp
gangliosid
receptor
ligand
cholera
toxin
b
evalu
sublingu
nasal
intraderm
adjuv
hiv
tt
ova
vaccin
mice
suggest
differ
adjuv
show
differ
immunolog
effect
upon
administr
differ
rout
bal
et
al
buffa
et
al
adjuv
consid
compon
vaccin
product
licens
separ
current
licens
adjuv
includ
alum
aluminum
sulfat
phosphat
squalen
droplet
two
surfact
aluminum
hydroxid
monophosphoryl
lipid
squalen
tween
virosom
lipid
hemagglutinin
select
develop
empir
review
adjuv
studi
proteinbas
vaccin
intranas
oral
administr
humansanim
summar
tabl
tabl
cholera
toxin
ct
heatlabil
enterotoxin
lt
alum
mpla
dsrna
polyriboinosinicpolyribocytidyl
acid
poli
c
surf
clam
microparticl
adjuv
compound
bi
cyclic
dimer
adenosineguanosineinosin
monophosph
cdiampgmpimp
muramyl
dipeptid
mdp
saponincontain
botan
extract
alum
base
adjuv
use
around
year
sinc
elicit
humor
immun
respons
upon
system
inject
adjuv
alum
liposom
show
synergist
effect
enhanc
immun
respons
dt
tt
oral
administr
rabbit
monkey
mirchamsi
et
al
gener
alum
weak
immunostimul
protein
antigen
mucos
vaccin
success
report
malik
et
al
moreov
hinder
potenti
use
vaccin
develop
intracellular
pathogen
tumor
due
incap
induc
potent
ctl
respons
marrack
et
al
reed
et
al
two
bacteri
toxin
cholera
toxin
ct
two
subunitscta
ctb
variou
strain
vibrio
cholera
heatlabil
enterotoxin
lt
enterotoxigen
strain
escherichia
coli
detoxifi
mutant
like
use
typic
mucos
adjuv
vaccin
protein
antigen
known
increas
epithelium
permeabl
modul
vaccin
uptak
apc
respons
lymphocyt
cox
et
al
although
use
nontox
mutant
adjuv
still
attract
improv
immunogen
antigen
morri
et
al
moscho
et
al
stephenson
et
al
adjuv
approv
human
intranas
vaccin
due
danger
redirect
antigen
central
nervou
system
caus
inflammatori
respons
bell
palsi
van
ginkel
et
al
mutsch
et
al
lewi
et
al
nevertheless
potenc
mucos
adjuv
put
gold
evalu
standard
mani
vaccin
develop
research
monophosphoryl
lipid
mpl
deriv
lipopolysaccharid
lp
salmonella
minnesota
pamp
induc
humor
cellular
immun
respons
system
mucos
vaccin
mataharo
et
al
lp
adjuv
ova
ntrimethyl
chitosan
tmc
nanoparticl
induc
higher
iga
titer
intranas
vaccin
mice
without
lp
bal
et
al
similarli
encapsul
mpla
togeth
ova
plga
nanoparticl
increas
antigenspecif
immun
respons
mice
oral
administr
compar
one
without
mpla
sarti
et
al
mpla
first
tlr
ligand
approv
human
vaccin
compon
vaccin
formul
hpv
hbv
kanzler
et
al
mataharo
et
al
apart
mpl
also
compon
sever
adjuv
glase
clinic
test
human
vaccin
maisonneuv
et
al
muramyl
dipeptid
mdp
peptidoglycan
constitu
gramposit
gramneg
bacteria
pamp
activ
nlr
turn
lead
cytokin
activ
howev
use
mdp
adjuv
limit
veterinari
vaccin
due
pyrogen
effect
human
lemesr
et
al
maisonneuv
et
al
intranas
vaccin
mice
mdp
adjuv
ova
tmc
nanoparticl
induc
higher
iga
titer
without
adjuv
bal
et
al
suggest
load
effici
small
substanc
like
immunostimul
mdp
tmc
nanoparticl
may
decreas
coload
larg
watersolubl
molecul
like
protein
ova
presum
caus
increas
leakag
mdp
diffus
channel
gener
leakag
ova
formul
prepar
mathew
et
al
bacteri
second
messeng
cyclic
dinucleotid
eg
cdiamp
cdigmp
suggest
promis
cytokin
tnf
mutant
regard
less
toxic
sinc
human
innat
substanc
combin
fendrix
liposom
mpl
oilinwat
emuls
mpl
alum
mpl
fendrix
liposom
mpl
cpg
make
use
synergist
effect
differ
adjuv
current
statu
clinic
studi
adjuv
indic
phase
phase
phase
licens
product
trade
name
tabl
summar
gener
adjuv
proteinbas
vaccin
mention
review
inform
regard
detail
investig
report
found
tabl
proteinbas
mucos
vaccin
review
mucos
adjuv
report
interact
transmembran
protein
stimul
interferon
gene
sting
increas
product
type
interferon
drive
adapt
immun
respons
ishikawa
et
al
burdett
et
al
shaw
et
al
studi
intranas
deliveri
model
protein
antigen
recombin
influenza
nucleoprotein
rnp
ova
togeth
adjuv
cdiampimp
mice
suggest
potent
mucos
adjuv
especi
cellular
immun
desir
ebensen
et
al
libanova
et
al
ebensen
et
al
sanchez
et
al
cdigmp
enhanc
immun
respons
mice
virosom
sublingu
intranas
intramuscular
administr
pedersen
et
al
cpg
motif
consid
pamp
sinc
abund
microbi
genom
vertebr
synthet
cpg
oligonucleotid
agonist
induc
product
apc
subsequ
stimul
antigenspecif
cellular
immun
respons
involv
ctl
krieg
et
al
klinman
et
al
use
clinic
test
compon
hbv
anthrax
prophylact
vaccin
kanzler
et
al
cpg
suggest
suitabl
adjuv
intranas
oral
vaccin
protein
antigen
hbsag
mccluski
davi
tt
mccluski
et
al
eastcott
et
al
hiv
peptid
pun
et
al
buffa
et
al
test
mice
poli
c
synthet
analogu
doubl
strand
viral
rna
activ
macrophag
dc
promot
strong
cell
prime
trumpfhel
et
al
suggest
potent
potenti
adjuv
nasal
influenza
vaccin
antigen
ha
evidenc
induc
compar
immun
respons
cpg
standard
adjuv
ctb
also
crossprotect
observ
mice
intranas
vaccin
ichinoh
et
al
similarli
play
vital
role
effici
induc
system
mucos
immun
protect
human
parainfluenza
virus
hpiv
intranas
vaccin
mice
oligomannoseco
liposom
oml
encapsul
fulllength
hana
hn
protein
antigen
senchi
et
al
small
molecul
polym
subunit
microb
act
immunostimul
virosom
assembl
membran
lipid
protein
influenza
viru
also
act
vaccin
adjuv
enhanc
immun
respons
intranas
vaccin
mice
simianhuman
immunodefici
virusvlp
shivvlp
antigen
influenza
virosom
adjuv
induc
compar
humor
cellular
immun
respons
adjuv
cpg
kang
et
al
synthet
small
organ
molecul
imidazoquinolin
compound
vitamin
e
tpg
glycolipid
imidazoquinolin
imiquimod
gardiquimod
synthet
agonist
imiquimod
abl
induc
balanc
humor
cellular
immun
respons
codeliv
hbsag
chitosan
nanocapsul
upon
intranas
vaccin
mice
vicent
et
al
compound
mast
cell
activ
compound
shown
safe
effect
nasal
adjuv
mice
coadminist
botulimun
neurotoxin
bonta
immunogenhcbtr
rabbit
coadminist
recombin
ha
meng
et
al
staat
et
al
vitamin
e
tpg
polyethylen
glycol
succin
water
solubl
vitamin
e
deriv
suggest
promis
nasal
vaccin
potenti
encapsul
dt
togeth
pcl
test
mice
somavarapu
et
al
alphagalactosylceramid
natur
glycolipid
deriv
murin
spong
mainli
chemic
synthes
present
apc
potent
activ
natur
killer
nkt
cell
modul
cell
immun
effici
activationmatur
dc
kawano
et
al
courtney
et
al
report
repeat
dose
intranas
oral
induc
potent
system
mucos
immun
respons
mice
hiv
epitop
peptid
antigen
courtney
et
al
saponin
plantderiv
chemic
compound
variou
biolog
pharmaceut
activ
amphipath
hydrophil
glycosid
moieti
lipophil
triterpen
deriv
saponin
extract
stimul
immun
respons
ctl
product
antigen
suggest
potenti
adjuv
vaccin
intracellular
pathogen
tumor
cell
yet
restrict
human
vaccin
usag
due
toxic
instabl
haemolyt
effect
purifi
fraction
qs
use
clinic
trial
skene
sutton
sun
et
al
purifi
qs
approv
commerci
use
veterinari
vaccin
like
bovin
respiratori
syncyti
viru
vaccin
elli
et
al
semisynthet
saponin
analog
potent
mucos
adjuv
induc
system
mucos
immun
respons
subcutan
intranas
administr
mice
nonfibril
adhesin
hemagglutinin
b
hagb
intranas
immun
potenc
found
second
lt
mutant
higher
test
adjuv
mpla
alum
ctb
subunit
ha
influenza
vaccin
adjuv
plant
lipid
monoolein
oleic
acid
lauric
acid
soybean
oil
could
induc
protect
immun
upon
intranas
administr
mice
petersson
et
al
shuje
wang
et
al
polym
crustacean
shell
eg
chitosan
particl
surf
clam
chitosan
deacetyl
deriv
polysaccharid
chitin
extract
crustacean
shell
mucoadhes
polym
prolong
mucos
resid
increas
uptak
vaccin
apc
chitosancontain
vaccin
subject
human
clinic
trial
suggest
lowtox
illum
et
al
moscho
et
al
sui
et
al
report
influenza
vaccin
use
chitosan
adjuv
induc
crossprotect
influenza
viru
infect
intranas
vaccin
mice
sui
et
al
surf
clam
microparticl
smp
process
surf
clam
shell
report
induc
humor
mucos
immun
respons
intranas
administ
influenza
ha
vaccin
mice
ichinoh
et
al
interleukin
il
cytokin
secret
apc
upon
antigen
stimul
potent
induc
product
nk
cell
lead
cell
develop
cell
trinchieri
boyaka
et
al
report
effect
adjuv
intranas
immun
mice
antigen
tt
boyaka
et
al
cytokin
famili
adjuv
found
abl
increas
haspecif
igg
titer
serum
iga
titer
mucos
surfac
intranas
immun
mice
compar
one
variou
adjuv
combin
one
formul
exploit
synergi
activ
immun
system
sever
adjuv
use
system
administr
either
licens
clinic
trial
develop
immunostimunl
combin
adjuv
system
seri
glaxosmithklin
contain
two
compon
alum
mpl
cpg
moscho
et
al
report
adjuv
chitosan
nlr
ligandmdp
contribut
synergist
increas
immunogen
recombin
h
pylori
ureas
rure
intranas
vaccin
mice
moscho
et
al
coadjuv
cdigmp
chitosan
show
balanc
th
immun
respons
mice
vaccin
antigen
ha
intranas
administr
svindland
et
al
unlik
small
molecul
protein
macromolecul
contain
primari
secondari
tertiari
even
quaternari
structur
labil
bond
specif
sidechain
orient
harsh
biolog
condit
eg
proteolyt
harsh
gastric
ph
could
caus
protein
denatur
degrad
could
reduc
biolog
activ
even
gener
advers
immunogen
therefor
usag
deliveri
system
andor
immunostimul
critic
import
facilit
induct
potent
longlast
immun
protect
mucos
vaccin
exampl
v
subunit
antigen
pesti
induc
humor
mucos
immun
intranas
administr
mice
coencapsul
pla
microspher
coadministr
use
ctb
adjuv
free
solubl
v
form
absenc
adjuv
eyl
et
al
although
appropri
particl
size
optim
mucos
vaccin
remain
determin
particul
antigen
gener
present
immunogen
mucos
vaccin
solubl
counterpart
challacomb
et
al
igartua
et
al
singh
ohagan
kopinghoggard
et
al
park
et
al
smith
et
al
marasini
et
al
van
riet
et
al
zhao
et
al
despit
limit
mechanist
understand
behavior
vivo
particul
deliveri
system
offer
sever
benefit
mucos
vaccin
includ
prevent
antigen
degrad
elev
concentr
antigen
vicin
mucosa
tissu
prolong
resid
releas
time
vaccin
codeliveri
antigen
adjuv
receptorligand
mediat
target
deliveri
act
immunepotenti
time
zhao
et
al
function
could
optim
adjust
control
properti
size
geometri
surfac
properti
molecular
pattern
antigen
load
surfac
decor
function
molecul
antigenreleas
kinet
bachmann
jen
intranas
oral
administr
vaccin
use
particul
deliveri
system
describ
sever
review
sharma
et
al
sun
et
al
marasini
et
al
focu
materi
vehicl
current
appli
develop
protein
antigenbas
vaccin
summar
tabl
tabl
includ
vlp
synthet
polym
poli
lacticcoglycol
acid
plga
poli
lactic
acid
pla
poli
pcl
poli
ethylen
glycol
peg
coatedconjug
copolym
like
pegplga
pegpla
pegpcl
polyethyleneimin
pei
natur
polym
deriv
chitosan
algin
lipidbas
vehicl
includ
liposom
niosom
bilosom
virosom
immunestimul
complex
iscom
other
multipl
antigenpres
vaccin
system
hydrogel
inorgan
vehicl
gold
nanoparticl
materi
vehicl
explor
vaccin
deliveri
system
encapsul
adsorb
conjug
protein
antigen
withwithout
adjuv
detail
variou
deliveri
system
vaccin
reader
refer
review
rydel
et
al
starch
vlp
diamet
nm
pseudoviron
selfassembl
viral
envelop
capsid
protein
biocompat
biodegrad
gener
regard
safe
well
establish
formul
techniqu
chemic
modif
particul
prepar
polym
protect
encapsul
antigen
harsh
environ
ph
sensit
suitabl
colon
deliveri
eg
eudragit
coat
abl
codeliv
immunostimul
antigen
load
capac
may
limit
due
intrins
chemic
properti
polym
antigen
chitosan
algin
starch
dextran
hyaluron
acid
natur
resourc
gener
nontox
biocompat
biodegrad
mucoadhes
immunostimul
eg
chitosan
work
deliveri
materi
coat
surfac
deliveri
vehicl
mucoadhes
materi
liposom
numer
licens
product
niosom
bilosom
virosom
epax
inflex
v
iscom
archaeosom
well
establish
formul
techniqu
surfac
modif
enhanc
vaccin
retent
mucos
sampl
uptak
process
apc
capabl
induc
humor
cellular
immun
respons
flexibl
encapsul
adsorpt
antigen
adjuv
load
capac
vari
chemic
properti
like
hydrophob
antigen
adjuv
chang
dendrit
scaffold
eg
lysinebas
dendrim
nonimmunogen
biocompat
incorpor
multiepitop
multifunct
peptid
one
system
increas
antigen
stabil
uptak
immunogen
cation
cholesteryl
groupbear
pullulan
cchp
gelvac
prolong
mucos
clearanc
effici
trap
protein
antigen
nanogel
suitabl
vaccin
lyophil
formul
gold
nonimmunogen
biocompat
easi
fabric
size
shape
receptorligand
mediat
deliveri
rgd
peptid
gangliosid
ligand
fc
mannos
igg
transferrin
enhanc
mucosa
permeabl
increas
specif
mucosalimmun
cell
uptak
mediat
receptorligand
interact
current
statu
clinic
studi
materi
indic
phase
phase
phase
licens
product
trade
name
tabl
summar
gener
deliveri
materi
proteinbas
vaccin
mention
review
inform
regard
detail
investig
report
found
tabl
shuje
wang
et
al
display
structur
characterist
virus
infecti
replic
due
lack
viru
gene
scheerlinck
greenwood
highli
immunogen
due
particular
order
repetit
structur
charact
mimick
natur
viru
constitut
protein
produc
mammalian
cell
insect
cell
yeast
bacteria
even
plant
recombin
dna
techniqu
santi
et
al
zhao
et
al
bear
properti
vlp
exploit
deliveri
system
proteinpeptid
antigen
sinc
display
multipl
epitop
infecti
pathogen
surfac
constitut
protein
via
genet
fusion
chemic
conjug
fuse
influenza
extracellular
region
hbv
core
protein
effici
express
e
coli
spontan
form
vlp
purif
vlp
induc
effici
protect
immun
influenza
viru
mice
intraperiton
intranas
administr
neirynck
et
al
de
filett
et
al
ibanez
et
al
vlp
assembl
recombinantli
modifi
capsid
protein
hev
found
hiv
immunogen
sinc
incorpor
peptid
sequenc
hiv
escap
preexist
antihev
immun
epitop
hev
capsid
protein
mutat
jariyapong
et
al
vlp
modular
murin
polyomaviru
mupyv
report
effici
antigen
deliveri
system
peptid
antigen
group
streptococcu
ga
sinc
fuse
antigenvlp
success
induc
immun
protect
mice
upon
intranas
vaccin
without
adjuv
riverahernandez
et
al
vlp
deriv
enter
pathogen
like
norwalk
viru
nv
believ
promis
deliveri
candid
oral
intranas
vaccin
mason
et
al
ball
et
al
guerrero
et
al
although
vlp
necessarili
need
extra
adjuv
vaccin
research
shown
vlp
immunostimul
detoxifi
ct
vlptrap
nucleic
acid
gmcsf
ligand
induc
better
immun
protect
de
filett
et
al
skountzou
et
al
ibanez
et
al
vlp
licens
commerci
diseas
caus
hepat
b
viru
hbv
krugman
scolnick
et
al
human
papillomaviru
hpv
shankretzlaff
et
al
deschuyten
et
al
hepat
e
viru
hev
li
et
al
wu
et
al
despit
success
usag
potent
immun
vlp
deliveri
system
protein
antigen
still
limit
rel
complic
genet
modif
protein
fusion
subsequ
requir
structur
integr
character
meanwhil
lipid
protein
express
host
may
also
assembl
vlp
thu
variou
express
system
could
gener
differenti
vlp
despit
fact
assembl
primarili
viral
protein
grgacic
anderson
polyest
plga
pla
pcl
base
particular
system
plga
one
success
adopt
biodegrad
polym
therapeut
vaccin
deliveri
embrac
sever
attract
properti
biodegrad
biocompat
gener
regard
safe
use
drug
deliveri
system
parenter
administr
welldevelop
techniqu
methodolog
encapsul
drug
variou
physiochem
properti
protect
drug
degrad
control
surfac
modif
control
sustain
releas
plga
microspher
nanoparticl
explor
deliveri
system
mucos
vaccin
develop
protein
antigen
plga
microparticl
contain
ova
elicit
sustain
ovaspecif
humor
mucos
immun
cattl
intranas
administr
kavanagh
et
al
mice
oral
deliveri
especi
immunostimul
mpla
coencapsul
sarti
et
al
multipl
oral
vaccin
ova
encapsul
plga
particl
stimul
ctl
immun
respons
mice
although
effici
formul
ova
iscom
maloy
et
al
mansoor
et
al
report
plga
particl
encapsul
bovin
parainfluenza
viru
peptid
protein
induc
earli
gradual
increas
humor
immun
respons
via
intranas
deliveri
suggest
advantag
slow
prolong
releas
antigen
particul
system
compar
solubl
form
mansoor
et
al
two
peptid
antigen
bovin
respiratori
syncyti
viru
brsv
coencapsul
plga
microparticl
induc
mucos
immun
respons
upper
lower
respiratori
tract
tcell
mediat
immun
respons
mice
singledos
intranas
administr
observ
solubl
antigen
kavanagh
et
al
peptid
antigen
malaria
carri
plga
microparticl
induc
stronger
system
immun
respons
compar
absorb
alum
either
oral
subcutan
administ
mice
meanwhil
cellular
immun
respons
observ
previou
formul
carcaboso
et
al
anoth
studi
recombin
envelop
protein
classic
swine
fever
viru
antigen
encapsul
plga
microspher
rabbit
serum
albumin
protein
stabil
mucos
system
vaccin
develop
brandhonneur
et
al
immun
test
realiz
rabbit
three
rout
intranas
oral
intramuscular
follow
intraderm
boost
respons
intranas
administr
found
stabl
intens
oral
rout
proteinpeptidebas
vaccin
orand
v
antigen
pesti
induc
higher
humor
mucos
immun
respons
mice
upon
intranas
administr
use
plgapla
microspher
deliveri
system
compar
solubl
antigen
eyl
et
al
alpar
et
al
tripathi
et
al
vaccin
intranas
rout
mice
induc
maintain
longliv
protect
immun
challeng
pesti
uleri
et
al
equi
mlike
protein
sem
antigen
encapsul
pcl
nanospher
contain
mucoadhes
polym
chitosan
algin
absorpt
enhanc
spermin
oleic
acid
develop
vaccin
equin
infect
florindo
et
al
vaccin
formul
induc
higher
immun
respons
free
antigen
mice
intranas
administr
pcl
nanoparticl
encapsul
dt
induc
higher
dtspecif
igg
respons
mice
intranas
immun
plgaplgapcl
blendcopolym
nanoparticl
attribut
increas
antigen
uptak
cell
hydrophob
pcl
nanoparticl
surfac
properti
plga
pla
pcl
particl
modifi
hydrophil
peg
posit
charg
chitosanpei
enhanc
protein
antigen
deliveri
exampl
ova
encapsul
pegyl
plgabas
nanoparticl
prepar
mix
polym
plga
plgapeg
pclpeg
report
induc
ovaspecif
igg
respons
mice
oral
administr
garinot
et
al
nanoparticl
pegplapeg
copolym
report
effici
oral
deliveri
hbsag
induc
higher
system
mucos
immun
mice
pla
nanoparticl
jain
et
al
radiolabel
tt
antigen
load
pla
plapeg
nanoparticl
intranas
administr
rat
found
hydrophil
plapeg
nanoparticl
show
significantli
increas
stabil
mucos
fluid
enhanc
mucosa
permeabl
antigen
compar
hydrophob
pla
nanoparticl
tobio
et
al
vila
et
al
meanwhil
plapeg
nanoparticl
perform
better
protein
carrier
antigen
transport
microparticl
vila
et
al
chitosan
modifi
plga
microparticl
show
prolong
resid
time
particl
intranas
mucosa
compar
nonmodifi
one
rabbit
hbsag
encapsul
system
induc
humor
cellular
mucos
immun
mice
intranas
administr
jaganathan
vya
similarli
hbsag
encapsul
pei
modifi
plga
microspher
induc
enhanc
immun
respons
mice
pulmonari
administr
compar
nonmodifi
one
thoma
et
al
wegmann
et
al
suggest
pei
microparticl
could
serv
potent
mucos
system
deliveri
system
intrins
adjuv
viral
glycoprotein
antigen
wegmann
et
al
sheppard
et
al
pei
investig
protein
antigen
deliveri
system
promot
crosspresent
mhc
pathway
use
antigen
model
ova
chen
et
al
studi
robust
antibodymedi
protect
induc
mice
rabbit
singl
intranas
administr
influenza
ha
herp
simplex
viru
type
glycoprotein
gp
use
pei
nanocarri
adjuv
wegmann
et
al
oral
deliveri
protein
vaccin
drug
target
gutassoci
lymphoid
tissu
galt
need
surpass
highli
acid
proteolyt
environ
gi
tract
case
specif
phsensit
polym
like
eudragit
often
adopt
eudragit
methacrylatebas
polym
design
dissolv
specif
ph
rang
depend
polym
chemistri
liu
et
al
report
eudragit
coat
calcium
algin
gel
bead
suffici
oral
proteinpeptid
drug
deliveri
target
colon
region
trap
algin
bead
peptid
drug
first
load
protect
liposom
liu
et
al
zhu
et
al
success
deliv
hiv
env
epitopebas
peptid
antigen
larg
intestin
mice
oral
administr
zhu
et
al
realiz
encapsul
peptid
antigen
micros
agglomer
plga
nanoparticl
follow
granul
eudragit
enter
polym
dissolv
ph
antigen
eudragit
formul
given
oral
induc
compar
immun
protect
antigen
administ
colorect
chitosan
chitosan
deriv
long
evalu
suitabl
mucos
deliveri
materi
proteinpeptid
drug
gene
therapi
garciafuent
alonso
recent
chitosan
base
system
also
evalu
potenti
adjuv
vaccin
deliveri
system
mucosa
vaccin
illum
et
al
van
der
lubben
et
al
muzzarelli
kobayashi
et
al
immunostimul
abil
chitosan
induc
mix
immun
respons
still
controversi
depend
administr
rout
shibata
et
al
porporatto
et
al
oliveira
et
al
antigen
tt
ntrimethyl
chitosanmononcarboxymethyl
chitosan
tmcmcc
complex
nanoparticl
induc
humor
cellular
immun
respons
mice
intranas
administr
sayin
et
al
vicent
et
al
report
chitosan
nanocapsul
codeliveri
system
oili
inner
core
carri
hydrophob
immunostimul
imiqimod
cation
chitosan
corona
absorb
anion
hbsag
surfac
codeliveri
system
induc
balanc
humor
cellular
immun
respons
mice
intranas
vaccin
vicent
et
al
sever
aspect
regard
properti
chitosan
might
need
improv
includ
target
specif
even
size
distribut
solubl
physiolog
environ
sahdev
et
al
algin
biocompat
biodegrad
mucoadhes
polym
could
also
serv
protein
deliveri
vehicl
algin
coat
chitosan
nanoparticl
could
serv
review
shuje
wang
et
al
potenti
mucos
vaccin
deliveri
system
prevent
load
protein
antigen
enzymat
degrad
intranas
oral
deliveri
recombin
hbsag
use
system
cpg
adjuv
effici
elicit
humor
mucos
immun
respons
mice
borg
et
al
borg
et
al
algin
microparticl
observ
effect
protein
antigen
deliveri
respiratori
diseas
intranas
administr
oral
rout
cattl
rebelatto
et
al
chitosan
nanoparticl
coat
lectin
algin
found
effici
oral
deliveri
system
antigen
bsa
target
mcell
success
induc
system
mucos
immun
mice
malik
et
al
tafaghodi
et
al
evalu
dri
powder
vaccin
formul
tt
encapsul
algin
microspher
intranas
immun
rabbit
tafaghodi
rastegar
result
suggest
algin
microspher
qs
adjuv
crosslink
dextran
microspher
adsorpt
enhanc
coordin
increas
titer
system
igg
mucos
siga
compar
intranas
immun
oral
vaccin
polyacryl
starch
microparticl
conjug
hsa
wikingsson
sjoholm
dt
rydel
sjoholm
nontox
mutant
could
induc
rel
stronger
system
mucos
antibodi
respons
mice
result
suggest
polyacryl
starch
microparticl
promis
oral
adjuv
protein
antigen
formaldehyd
treatment
dt
mutant
conjug
microparticl
induc
better
immun
respons
revers
order
unlik
microparticl
protect
protein
antigen
degrad
silicon
graft
starch
observ
facilit
releas
encapsul
hsa
increas
mucos
immunogen
oral
intranas
administr
mice
mcdermott
et
al
dextran
complex
branch
glucan
product
microbi
ferment
mucoadhes
act
mucosa
permeat
enhanc
protein
vaccin
deliveri
instanc
tt
encapsul
crosslink
dextran
microspher
cdm
adjuv
cpg
induc
potent
system
igg
mucos
iga
immun
respons
rabbit
intranas
administr
alum
absorb
tt
fail
induc
potent
mucos
iga
secret
sajadi
tabassi
et
al
hyaluron
acid
hyaluronan
natur
compon
cartilag
linear
polysaccharid
compris
repeat
disaccharid
unit
dglucoron
acid
nacetyldglucosamin
particip
immun
reaction
modul
traffick
leukocyt
matur
epiderm
dc
activ
tcell
antigen
present
mummert
explor
protein
vaccin
deliveri
due
excel
safeti
biocompat
biodegrad
hydrophil
mucoadhes
sahdev
et
al
intranas
administr
influenza
ha
adjuv
detoxifi
lt
use
esterifi
hyaluron
acid
hyaff
microspher
system
induc
potent
immun
respons
mice
rabbit
smallpig
convent
intramuscular
immun
meanwhil
hyaff
microspher
formul
induc
higher
antibodi
titer
vivo
solubl
mix
antigen
adjuv
singh
et
al
gammapolyglutam
acid
high
molecular
weight
polym
glutam
acid
linkag
amino
group
carboxyl
side
chain
natur
product
bacteri
ferment
major
constitu
tradit
japanes
food
natto
appli
medicin
vaccin
applic
due
good
biocompat
low
cytotox
hydrophil
hydrophob
modifi
lphenylalanin
ethyl
ester
lpae
produc
amphipath
ovaencapsul
nanoparticl
induc
ovaspecif
antitumor
immun
mice
intranas
vaccin
matsuo
et
al
although
result
show
similar
total
igg
titer
immun
nanoparticleencapsul
free
vaccin
antigen
deliv
nanoparticl
system
effici
induc
antigenspecif
cellular
immun
respons
spleen
lymph
node
recent
nanomicel
system
selfassembl
cholesterol
conjug
deriv
observ
abl
serv
mucu
deliveri
cellularimmunityinduc
adjuv
protein
antigen
ova
noh
et
al
besid
polymer
particul
deliveri
system
mention
anoth
larg
group
deliveri
vehicl
base
lipid
lipid
microparticl
report
success
intranas
deliveri
system
introduc
mucos
immun
respons
hbsag
rat
saraf
et
al
similar
abovement
polym
lipid
microparticl
could
prepar
soya
lecithin
without
stearylamin
use
doubl
emuls
method
yet
lipidbas
vehicl
prepar
form
liposom
drug
vaccin
deliveri
accord
sourc
properti
constitu
materi
liposom
could
name
normal
liposom
niosom
bilosom
virosom
archaeosom
iscom
liposom
artifici
vesicl
one
layer
phospholipid
intern
aqueou
core
wide
use
deliveri
therapeut
vaccin
due
proven
safeti
biocompat
eas
manufactur
torchilin
depend
hydrophil
hydrophil
antigen
protein
peptid
carbohydr
entrap
within
inner
aqueou
caviti
liposom
hydrophob
antigen
lipoprotein
lipophil
adjuv
insert
lipid
membran
besid
antigen
adjuv
also
conjug
adsorb
liposom
surfac
larg
unilamellar
liposom
nm
diamet
gener
stabl
smaller
counterpart
nm
due
low
curvatur
less
surfac
tension
dawidczyk
et
al
dt
tt
load
liposom
induc
neutral
antibodi
respons
rabbit
monkey
oral
administr
adjuv
alum
mirchamsi
et
al
ha
load
liposom
system
use
deliv
hbsag
intranas
mice
show
higher
mucos
uptak
stronger
mucos
cellular
immun
respons
compar
intranas
administ
placebo
intramuscularli
administ
mix
ha
alum
system
tiwari
et
al
modifi
liposom
found
abl
mediat
antigen
target
cell
lead
enhanc
system
mucos
immun
respons
mice
oral
intranas
administr
compar
nonmodifi
one
encapsul
fluoresc
label
model
antigen
bsa
clark
et
al
li
et
al
li
et
al
iggcoupl
liposom
encapsul
hbsag
report
induc
system
mucos
immun
escal
antigen
uptak
cell
upon
intranas
vaccin
mice
alumadsorb
hbsag
unabl
induc
immun
respons
administ
intramuscularli
tiwari
et
al
minato
et
al
found
dose
pegmodifi
liposom
encapsul
ova
significantli
affect
balanc
system
mucos
immun
respons
mice
oral
administr
minato
et
al
attribut
differ
releas
rate
intestin
mucosa
surfac
oligomannoseco
liposom
oml
induc
signific
system
mucos
immun
respons
mice
intranas
vaccin
encapsul
antigen
ova
effect
absent
noncoat
liposom
entrap
ova
ova
alon
ishii
kojima
oml
encapsul
fulllength
hana
protein
omlhn
induc
viralspecif
system
mucos
immun
human
parainfluenza
virus
hpiv
mice
intranas
vaccin
presenc
poli
c
senchi
et
al
synthet
oligomannos
suggest
use
mucos
adjuv
sinc
embrac
compar
effici
ctb
act
possibl
celltarget
mucos
adhes
materi
ishii
kojima
nonion
surfact
vehicl
nisv
niosom
nonbiolog
origin
chemicalbiolog
stabl
altern
liposom
share
similar
hydrophath
properti
liposom
explor
protein
vaccin
deliveri
niosom
use
deliv
glycoprotein
b
gb
polylysin
rich
peptid
dtk
herp
simplex
viru
hsv
intranas
mice
success
induc
humor
cellular
immun
protect
genit
herp
cortesi
et
al
niosom
incorpor
bile
salt
term
bilosom
bile
salt
lipid
bilay
could
stabil
bilosom
bile
acid
gastrointestin
tract
inner
aqueou
space
bilosom
could
entrap
vaccin
antigen
like
proteinspeptid
effici
oral
deliveri
test
ha
mann
et
al
hbsag
shukla
et
al
shukla
et
al
dt
tt
mann
et
al
shukla
et
al
jain
et
al
result
indic
bilosom
could
potenti
oral
deliveri
system
protein
antigen
sinc
signific
system
mucos
immun
observ
test
bilosom
induc
balanc
respons
oral
administr
could
modul
physic
modifi
size
bilosom
deliveri
vehicl
evidenc
studi
influenza
antigen
ha
test
mice
ferret
mann
et
al
archaeosom
prepar
archaeal
lipid
also
believ
promis
mucos
vaccin
adjuv
deliveri
system
encapsul
protein
antigen
protein
antigen
ova
encapsul
system
induc
humor
immun
respons
mucos
immun
intranas
administr
mice
patel
et
al
addit
multival
cation
like
cacl
abl
convert
protein
antigen
load
archaeosom
nm
diamet
archaeal
lipid
mucos
vaccin
adjuv
deliveri
amvad
system
patel
chen
amvad
larger
aggreg
structur
diamet
less
like
bunch
grape
ova
encapsul
amvad
system
could
induc
potent
long
last
antigenspecif
humor
mucos
local
remot
site
ctl
respons
mice
intranas
immun
patel
et
al
patel
et
al
amvad
system
believ
rel
safe
vaccin
deliveri
system
intranas
administr
test
excess
dose
requir
vaccin
efficaci
patel
et
al
amvad
system
could
advantag
liposom
due
high
load
effici
hydrophil
protein
antigen
insid
archaeosom
inbetween
increas
stabil
autoxid
sinc
archaeal
lipid
consist
satur
side
chain
instead
unsatur
form
addit
immunostimul
adjuv
requir
virosom
consist
viral
surfac
protein
eg
ha
na
influenza
viru
embed
lipid
membran
intern
gene
materi
thu
cell
fusion
activ
replic
abil
explor
drug
vaccin
deliveri
vector
pederson
et
al
evalu
vaccin
effect
influenza
virosom
sublingu
intranas
intramuscular
administr
mice
adjuv
cdigmp
sublingu
intranas
vaccin
induc
better
local
mucos
system
cellular
immun
respons
intramuscular
administr
respons
intranas
rout
stronger
sublingu
one
pedersen
et
al
immunestimul
complex
iscom
document
deliveri
system
immunostimul
vaccin
develop
iscom
nm
nanovector
open
cage
structur
compris
cholesterol
phospholipid
mixtur
saponin
extract
quillaja
saponaria
molina
sander
et
al
skene
sutton
sun
et
al
vaccin
iscom
induc
system
mucos
immun
respons
upon
intranas
administr
incorpor
protein
antigen
respiratori
syncyti
viru
rsv
envelop
protein
hu
et
al
mycoplasma
mycoid
subsp
mycoid
mmmsc
prtoein
abusugra
morein
recombin
hbsag
pandey
dixit
initi
hydrophob
antigen
like
membran
protein
incorpor
iscom
morein
et
al
later
iscomatrix
develop
mix
antigen
circumv
incorpor
depend
antigen
properti
iscom
iscomatrix
induc
humor
ctl
respons
controversi
iscomatrix
scheerlinck
greenwood
although
immun
potenti
mechan
present
unclear
iscom
suggest
potenti
intranas
oral
vaccin
deliveri
system
protein
antigen
mowat
et
al
hu
et
al
tam
develop
multipl
antigen
peptid
map
system
use
nonimmunogen
lysinebas
dendrit
scaffold
improv
immunogen
subunit
peptid
vaccin
tam
map
system
found
abl
increas
stabil
uptak
immunogen
conjug
peptid
antigen
improv
immunogen
compon
variou
function
incorpor
map
helper
tcell
epitop
immunostimul
lipid
moieti
cellpenetr
peptid
fujita
taguchi
ali
et
al
report
b
epitop
carri
map
encapsul
plga
microspher
induc
strong
humor
mucos
immun
respons
mice
intranas
vaccin
signific
higher
mix
short
epitop
peptid
without
conjug
map
also
found
coadministr
encapsul
adjuv
cpg
significantli
increas
immun
plagu
infect
ali
et
al
nanos
hydrogel
cholesterylgroupbear
pullulan
chp
trap
protein
drug
antigen
nonaggreg
hydrophob
interact
gradual
releas
nativ
drug
antigen
polym
network
nochi
et
al
kong
et
al
report
cation
chp
cchp
nanogel
success
adjuvantfre
intranas
vaccin
carrier
protein
antigen
bohca
tt
pspa
prove
induc
antigenspecif
immun
protect
infecti
diseas
mice
group
found
vaccin
invas
olfactori
bulb
central
nervou
system
intranas
vaccin
suggest
cchp
nanogel
effect
safe
intranas
vaccin
deliveri
system
protein
antigen
nochi
et
al
kong
et
al
inert
situ
gell
polysaccharid
gelsit
extract
alo
vera
use
drypowd
vaccin
formul
gelvac
intranas
deliveri
norwalk
vlp
velasquez
et
al
studi
gelvac
formul
delay
mucociliari
clearanc
prolong
antigen
exposur
immun
effector
site
due
insitu
gelat
nasal
mucosa
gold
nanoparticl
use
deliv
subunit
vaccin
without
induc
antigold
antibodi
could
promot
immun
respons
via
differ
cytokin
pathway
depend
size
shape
vaccin
tt
load
chitosanfunctionalizedgold
nanoparticl
quillaja
saponaria
extract
adjuv
induc
immun
respons
mice
oral
administr
compar
one
without
use
nanoparticl
deliveri
system
barhat
et
al
vaccin
extracellular
domain
conjug
gold
nanoparticl
adjuv
cpg
induc
protect
immun
respons
influenza
viru
intranas
administr
mice
tao
et
al
mani
receptor
mucos
epitheli
cell
cell
apc
explor
vaccin
targetdeliveri
antigen
codeliv
specif
receptorbind
ligand
lectin
bacteri
adhesin
bacteri
toxin
pamp
mcell
target
ligand
antibodi
fc
takahashi
snehedri
et
al
cruz
et
al
devriendt
et
al
similarli
receptor
dc
target
dctarget
protein
fuse
cancer
antigen
protein
cancer
immunotherapi
et
al
ligand
fuse
antigen
directli
conjugatedabsorb
surfac
deliveri
system
et
al
exampl
highli
effici
transcytot
recycl
transferrin
receptor
locat
nasal
vagin
mucos
epithelium
thu
transferrin
util
drugvaccin
conjug
specif
target
qian
et
al
mann
et
al
transferrin
conjug
model
trimer
antigen
endow
vaccin
effici
mucos
target
especi
intranas
administr
mann
et
al
claudin
consider
express
tumor
cell
mucos
epithelium
cell
thu
explor
target
deliveri
tumor
therapi
mucos
vaccin
ova
fuse
bind
ligand
induc
immun
respons
mice
suggest
target
effect
way
intranas
vaccin
nagas
et
al
epitheli
cell
bind
domain
fuse
botulinum
neurotoxin
bonta
immunogenhcbtr
staat
et
al
fuse
induc
higher
antibodi
respons
rabbit
intranas
immun
compar
nonfus
hcbtre
antigen
alon
lectin
mediat
mucos
target
deliveri
bind
receptor
apic
membran
cell
lectin
plga
particl
encapsul
hbsag
enhanc
immun
respons
oral
administr
compar
nonlectin
one
gupta
et
al
mcell
home
peptid
identifi
phage
display
techniqu
significantli
increas
mcell
mediat
uptak
modifi
chitosan
nanoparticl
yoo
et
al
plga
nanoparticl
coat
significantli
enhanc
system
mucos
immun
respons
bmpb
protein
antigen
swine
dysenteri
vaccin
oral
administr
rgd
peptid
display
vaccin
deliveri
system
like
pegyl
plga
nanoparticl
target
apic
side
cell
use
oral
administr
mice
garinot
et
al
mcell
target
ligand
gangliosid
also
report
induc
increas
system
mucos
immun
respons
fuse
protein
antigen
oral
administr
mice
compar
nonfus
antigen
kim
et
al
kim
et
al
protein
ag
fuse
igg
fc
specif
target
igg
fcreceptor
constitut
express
apc
enhanc
humor
cellular
immun
nimmerjahn
ravetch
gosselin
et
al
plga
nanomicroparticl
surfacemodifi
dctarget
antibodi
peptid
improv
antigen
present
lewi
et
al
du
et
al
et
al
success
vaccin
mice
induc
strong
system
antibodi
respons
intramuscularsubcutan
administr
recombin
protein
contain
receptorbind
domain
rbd
sar
merscov
spike
protein
fuse
fc
igg
rbdfc
du
et
al
du
et
al
later
report
much
stronger
local
mucos
immun
respons
induc
intranas
vaccin
rbdfc
antigen
subcutan
immun
et
al
rbd
fusion
fc
also
confer
rbdfc
dimer
conform
du
et
al
et
al
may
improv
immunogen
mucos
vaccin
protein
antigen
promis
product
format
futur
vaccin
develop
especi
consid
desir
immun
protect
mucos
surfac
safeti
protein
antigen
howev
low
immunogen
weak
stabil
free
protein
antigen
rel
harsh
mucos
fluid
nasal
mucu
gastric
condit
requir
optim
vaccin
formul
enhanc
immun
protect
wide
rang
particul
deliveri
system
proven
effici
vaccin
deliveri
anim
human
coadministr
suitabl
immunostimul
protein
antigen
could
facilit
enhanc
gener
potent
antigenspecif
immun
protect
therefor
success
design
vaccin
therapeut
alway
optim
combin
antigen
immunopotenti
vaccin
carrier
effect
formul
deliv
appropri
administr
rout
current
research
suggest
mucos
deliveri
properli
design
formul
proteinbas
antigen
could
provid
effici
humor
protect
anim
model
nontheless
detail
mechan
differ
vaccin
therapeut
actual
gener
enhanc
vaccin
protect
still
await
investig
could
realiz
system
compar
effect
variou
formul
administ
rout
antigen
specificli
differ
deliveri
carrier
immunostimul
properti
size
geometri
vivo
kinet
molecular
pattern
contribut
mucos
sampl
vaccin
uptak
process
present
final
lead
desir
immun
meanwhil
research
effort
requir
design
mucos
vaccin
induc
strong
cellular
immun
includ
ctl
respons
especi
diseas
like
tuberculosi
hiv
malaria
cellular
immun
crucial
mediat
protect
